Welcome to our dedicated page for Clearmind Medici news (Ticker: CMND), a resource for investors and traders seeking the latest updates and insights on Clearmind Medici stock.
Clearmind Medicine Inc. (CMND) is a clinical-stage psychedelic pharmaceutical biotech company focused on developing novel neuroplastogen-derived and psychedelic-derived therapeutics, with a lead program targeting alcohol use disorder (AUD). The Clearmind news feed on Stock Titan highlights company announcements that trace the progress of its clinical pipeline, intellectual property strategy, and exchange listing status.
News items commonly cover key milestones in Clearmind’s FDA-approved Phase I/IIa clinical trial of CMND-100, its proprietary non-hallucinogenic MEAI-based oral candidate for AUD. These updates include cohort enrollment and completion, dosing at new clinical sites such as Yale School of Medicine, Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center, and decisions by the independent Data and Safety Monitoring Board to allow the trial to continue following interim safety reviews.
Investors following CMND news will also see disclosures on peer-reviewed publications discussing MEAI’s pharmacological and receptor interaction profile, as well as articles that compare MEAI with other psychedelics and entactogens in the context of AUD. In addition, Clearmind regularly reports on capital markets developments, such as registered direct offerings, reverse share splits, and notifications from Nasdaq regarding compliance with minimum bid price and stockholders’ equity requirements.
This news page allows readers to track how Clearmind’s clinical-stage activities, patent portfolio expansion, and listing compliance efforts evolve over time. For anyone monitoring CMND stock or the broader field of psychedelic and neuroplastogen-based therapeutics for addiction and mental health, the Clearmind news stream provides a centralized view of the company’s publicly reported developments.
Clearmind Medicine (Nasdaq: CMND) announced on March 30, 2026 the successful completion of treatment and follow-up for 18 participants in its FDA‑approved Phase I/IIa trial of CMND-100, a non‑hallucinogenic MEAI‑based oral candidate for Alcohol Use Disorder.
The company also treated four additional participants at its Tel Aviv site, and the multinational trial includes sites at Yale, Johns Hopkins, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.
Clearmind Medicine (Nasdaq: CMND) filed a patent application in India on March 27, 2026 for next‑generation, non‑hallucinogenic neuroplastogen‑derived compounds targeting mental health disorders and addiction.
The filing, with the Indian Patent Office, expands the company's global intellectual property portfolio and builds on its exclusive worldwide licensing agreement with Yissum, seeking protection for novel compounds designed to address limitations of classical psychedelics and enable potentially safer, scalable treatments.
Clearmind Medicine (Nasdaq: CMND) reported successful ongoing treatment of participants in the third cohort of its FDA-approved Phase I/IIa trial of CMND-100 for Alcohol Use Disorder (AUD) as of March 19, 2026. U.S. sites at Yale and Johns Hopkins continue treatment with no serious adverse events reported to date.
The multinational, multicenter study evaluates safety, tolerability, pharmacokinetics and preliminary efficacy of the company’s non-hallucinogenic, MEAI-based oral candidate in patients with moderate to severe AUD.
Clearmind Medicine (Nasdaq: CMND) announced publication of six patents in Hong Kong on March 17, 2026 covering proprietary combination therapies that integrate Palmitoylethanolamide (PEA) with six psychedelic compounds.
The patents protect formulations combining PEA with MDMA, LSD, ketamine, ibogaine, psilocybin, and DMT, and reflect a sourcing partnership with NeuroThera Labs. The company describes these combinations as intended to enhance therapeutic potential, safety, tolerability, and neuroplasticity profiles for mental health and neurological indications.
Clearmind Medicine (Nasdaq: CMND) on March 13, 2026 filed a patent application with Hong Kong IPD for a combination therapy pairing proprietary MEAI with Palmitoylethanolamide (PEA) to treat major depressive disorder (MDD).
The filing notes the PEA supply via a partnership with NeuroThera Labs (TSXV: NTLX), a SciSparc subsidiary, and positions the MEAI-PEA synergy as a non-hallucinogenic neuroplastogen approach targeting an MDD market projected above $25 billion by 2030.
Clearmind Medicine (Nasdaq: CMND) announced continued enrollment for Cohort 3 of its FDA-approved Phase I/IIa trial of CMND-100 for Alcohol Use Disorder on March 11, 2026. The move follows positive topline results from Cohort 2 and unanimous DSMB approval to proceed.
The multinational, multicenter study will expand recruitment at Yale, Johns Hopkins and Tel Aviv Sourasky Medical Center to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of the non-hallucinogenic MEAI-derived oral candidate.
Clearmind Medicine (Nasdaq: CMND) announced on March 10, 2026 the publication of an international PCT patent application for a novel, non-hallucinogenic combination therapy pairing MEAI with Palmitoylethanolamide (PEA) targeting weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD).
The company cites a collaboration with NeuroThera Labs and notes market context: global weight-loss drugs valued at ~$37B in 2025 and forecast to reach ~$226B by 2035. The filing is a patent publication, not a granted patent or clinical efficacy readout.
Clearmind Medicine (Nasdaq: CMND) reported that an independent Data and Safety Monitoring Board unanimously cleared progression of its FDA-approved Phase I/IIa trial of CMND-100 in Alcohol Use Disorder after a second interim review on March 4, 2026.
The DSMB found additional topline safety data from the second cohort — which used twice the dose of cohort one — acceptable and recommended moving to a third cohort dosed at 80 mg. The multinational, multicenter study continues to evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy.
Clearmind Medicine (Nasdaq: CMND) highlights preclinical and early clinical progress for its non‑hallucinogenic neuroplastogen MEAI as a potential brain‑targeted, oral approach to obesity and compulsive eating. Preclinical studies report ~20% weight reduction in diet‑induced obese mice, patents filed, a Polyrizon intranasal collaboration, and ongoing FDA‑approved Phase I/IIa trials for related indications.
The release is a paid promotional communication and stresses early‑stage status for weight‑loss indications despite promising metabolic and behavioral signals.
Clearmind Medicine (Nasdaq: CMND) reported additional positive topline safety results from the second cohort of its FDA‑approved Phase I/IIa trial of CMND‑100 for Alcohol Use Disorder (AUD) on February 9, 2026. The cohort completed treatment across multinational sites, showed no serious adverse events, and maintained good tolerability.
The company said the Data and Safety Monitoring Board gave unanimous clearance to advance the study, and investigators completed dosing at sites including Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.